True North Clinical Research

Providing Hope to Present and Future Generations

True North Clinical Research is committed to the health and wellness of patients living in Nova Scotia.

Why Clinical Research?

Clinical trials are an essential part of the research and development of all pharmaceutical drugs. All medication, whether sold through prescription or over-the-counter, must undergo comprehensive testing to ensure they treat the condition or conditions they were designed and created to treat without significant risk to those taking them.

Each and every trial we conduct is done so under strict guidelines, which are monitored by Health Canada. Health Canada approves the use of investigational medications within clinical trials, before these medications are approved for use by the general public. A Principal Investigator – a medical doctor trained to conduct research trials in a safe, ethical and controlled manner – oversees each of our research trials.

In order to qualify for a trial, participants are screened and must meet a strict criteria. Those participants who qualify to enroll in a trial will be required to attend a variety of appointments and their progress will be carefully tracked. During these visits, participants will work with our clinical staff and investigators. These visits could potentially include questionnaires, blood collection, physical exams, and diagnostic tests.

It should be noted that each participant is fully educated as to what to expect prior to undergoing any trial-related assessments that may be required.

Importance and Benefits of Participation

 

  • Contribution to the future development of medications worldwide
  • Access to potential treatment options that is currently not available to the general public
  • Constant monitoring and care provided by highly trained professionals
  • On-going support provided by clinical research staff
True North Clinical Memory and Alzheimer Conditions
How do I learn more?
If you are interested in learning more about clinical trials, or wish to inquire about out current or future trials, click here to contact us and one of our highly trained staff will be in touch to provide more information.

Recruiting Clinical Trials

Currently Recruiting New Participants
Alzheimer’s Disease – Eisai Clarity AD

True North Clinical Research is currently involved in a clinical trial with Eisai Co., Ltd. (known as “Eisai”) researching an investigational drug for early Alzheimer’s disease (AD) called BAN2401 (versus a placebo; a treatment that looks like the study drug but is not).

BAN2401 is an investigational study drug which is being studied in people who have early AD, with mild cognitive (thinking) impairment or mild dementia. People with AD have a build-up of an abnormal protein, known as amyloid, in their brains.  This build up may lead to impairment in memory or thinking.  

BAN2401 is what is known as a monoclonal antibody.  Antibodies are proteins produced by the immune system that bind to foreign substances in the body called antigens.  BAN2401 binds to amyloid in the brain in patients with AD and has been shown to reduce the amount of this abnormal protein.  In a different study, BAN2401 slowed the decline in cognition in some people. 

The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (how much the study drug improves symptoms and reduces amyloid in the brain) of the study drug in patients who have early AD.

The study will run for approximately 18 months. Participants who qualify for a study and agree to participate will receive bi-weekly (every two weeks) infusions of either the treatment or the placebo. Participation in the study is voluntary, and participants can withdraw at any time.

 
Alzheimer’s Disease – Biogen (redosing)

True North Clinical Research is involved in an open-label study to determine the long-term safety and efficacy of a medication (called aducanumab) in patients who were part of previous studies on that same medication. Aducanumab is an antibody that targets amyloid, a protein that builds up in the brains of people with Alzheimer’s disease. 

These studies were originally discontinued based on the belief that the medication didn’t slow the progression of Alzheimer’s disease sufficiently. A re-examination of the data by Biogen (the developer) indicated that those receiving higher doses of the medication showed slower cognitive and functional decline versus those receiving lower doses or the placebo. 

Those involved in this current study must have taken part in one of the previous studies.

 
Alzheimer’s Disease – Buena

True North Clinical Research is involved in a clinical trial with IntelGenX, researching an investigational medication vs placebo in those with mild-moderate Alzheimer’s disease. The investigational medication being studied is a repurposed drug that is already on the market (Montelukast) and the sponsor is looking at the potential of this drug to reduce neuroinflammation in an effort to slow down the progression of memory loss due to Alzheimer’s disease. Participants must already be taking an acetylcholinesterase inhibitor such as Aricept in order to qualify to participate in the trial. This trial is evaluating the relationship between the investigational medication and the cognitive abilities of participants over a 26 week period.

Alzheimer’s Disease – vTv

True North Clinical Research is involved in a clinical trial with vTv Therapeutics, researching an investigational medication vs placebo in those with mild Alzheimer’s disease and Type 2 diabetes not treated with insulin. The investigational medication being studied is designed to reduce inflammation in the brain and prevent the build up of beta-amyloid plaques that scientists believe cause Alzheimer’s Disease.  Participants are allowed to already be taking an acetylcholinesterase inhibitor such as Aricept and still participate in the trial. Participant’s that qualify will be enrolled in the study for approximately 11 months which includes 6 months of treatment (or placebo).

Osteoarthritis of the Knee – Antibe Therapeutics

True North Clinical Research is involved in a clinical trial with Antibe Therapeutics, researching an investigational medication vs placebo in those with Osteoarthritis of the knee. The investigational medication being studied is designed to reduce inflammation and pain without causing gastrointestinal upset, which is a side effect of other commonly used arthritis treatments such as Naproxen.  Participant’s that qualify will be enrolled in the study for up to46 days which includes 14 days of treatment (or placebo).

Ongoing Clinical Trials

Recruitment Closed

AZTherapies

True North Clinical Research is involved in a clinical trial with AZTherapies, researching investigational medications vs placebo in those with early evidence of Alzheimer’s disease. The investigational medications being studied are repurposed drugs that are already on the market (inhaled Cromolyn and Ibuprofen) and the sponsor is looking at the potential of these drugs, taken in combination, to prevent the formation of harmful plaques that are believed to cause Alzheimer’s and to reduce neuroinflammation in an effort to slow down the progression of memory loss due to Alzheimer’s disease. This trial is evaluating the relationship between the investigational medication and the cognitive abilities of participants over a 72 week(1 year and 6 months) period.

Marguerite Road

With Hoffman-La Roche, True North Clinical Research is involved in a clinical trial researching gantenerumab in patients with mild Alzheimer’s disease. This trial is evaluating the relationship between monthly subcutaneous infusions of gantenerumab (a monoclonal antibody) and the cognitive and functional abilities of trial participants. Gantenerumab is designed to remove beta-amyloid plaque from the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.

Scarlet Road

True North Clinical Research is involved in a clinical trial with Hoffman-La Roche, researching gantenerumab in patients with prodromal Alzheimer’s disease. This trial is evaluating the relationship between monthly subcutaneous infusions of gantenerumab (a monoclonal antibody) and the cognitive and functional abilities of trial participants. Gantenerumab is designed to remove beta-amyloid plaque from the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.

Completed Clinical Trials

True North Clinical Research has proudly participated in many trials that have the potential to impact the lives of hundreds of thousands of people around the globe. Below is a list of some of our completed trails.